Pure Global
NCT06255951

Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects

This is a Single-center, Two-sequence, Open-label, Two-cycle Drug-drug Interaction (DDI) Study in Healthy Subjects. To Evaluate the Effects of Itraconazole Capsules, a Strong Inhibitor of CYP3A4, and Rifampicin Capsules, a Strong Inducer, on the Pharmacokinetics of TY-9591 Tablets After a Single Oral Dose
TYK Medicines, Inc·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
NSCLC
Drug/Device/Intervention
Itraconazole
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
TYK Medicines, Inc
Location
Guangdong, China
Timeline & enrollment
Phase
Phase 1
Start date
Mar 04, 2024
End date
Aug 05, 2024
Enrollment
48 participants
Primary outcome

Peak plasma concentrations (Cmax) of TY-9591 and its metabolites D1 and D2,Area under the concentration-time curve from 0 to the last quantifiable time point after dose administration (AUC0-t),Area under the concentration-time curve from 0 to infinity (AUC0-inf), as data permit

Summary

Studies evaluating the effects of itraconazole or rifampicin on the pharmacokinetics of
 TY-9591 tablets in healthy subjects

Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06255951
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06255951 through Pure Global AI's free database. This Phase 1 trial is sponsored by TYK Medicines, Inc and is currently Recruiting. The study focuses on NSCLC. Target enrollment is 48 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.